Topic
Merck
Merck is a drug company that comes up in podcasts about biotech, cancer treatments, drug discovery and clinical trials. Speakers discussed its melanoma partnership with Moderna, its use of AI, and how it runs its trials.
Stéphane Bancel told a16z's Raising Health that Moderna and Merck hope to have their melanoma treatment available to patients in 2027. Ben Comer said on Business Of Biotech that Merck invested nearly $18 billion in research and development in 2024. Jennifer Sheller said she has been at Merck for over eight years and described its acquisitions of Peloton Therapeutics and Acceleron.
28 facts from 8 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
1990s
In the late 1990s, clinical research associates verified hospital records against handwritten triple-copy NCR paper forms, which later gave way to electronic data capture.
“when I first started in the late 90s, it was, you know, triple NCR paper. So we'd go out to the hospitals to make sure that the records in the hospital system matched what was handwritten on an NCR form.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:05:12
2015
According to Bancel, the individualized cancer treatment technology emerged from Moderna's labs around 2015-2016, when Moderna partnered with Merck.
“a technology that emerged from Moderna Labs back in 2015, 2016 when we did a partnership with Merck as we were looking for one of the best companies in immunotherapy to partner”
Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:08:25
2017
Jennifer Sheller joined Merck in 2017 and initially worked on integrating acquired companies' R&D activities into Merck's operations.
“You joined Merck in 2017, Jen, and initially, I think, worked on integrating acquired companies' R &D activities into Merck's R &D operations.”
Ben Comer · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:16:33
2021
Adam Feuerstein said Merck, Pfizer and another company were developing oral Covid antivirals, and that remdesivir's effect gave reason for optimism.
“oral antivirals that we've spoken about from Merck, a company called Atia Pharmaceuticals, and a company called Pfizer that are now in development”
Host · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:06:44
2024
Merck invested nearly $18 billion in research and development in 2024 and conducts trials in over 60 countries at more than 21,000 sites.
“a company that invested nearly $18 billion in R &D in 2024 and conducts trials in over 60 countries at more than 21 ,000 trial sites”
Ben Comer · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:00:06
2026
Sheller says Merck is resetting its operating model around risk-based quality management, with implementation planned for 2026.
“we're really focused, as I mentioned earlier, on resetting our operating model with risk-based quality management.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:52:52
2026
Bancel said the Moderna and Merck Phase 3 melanoma trial also met its secondary endpoint of distant metastasis-free survival at the first interim analysis.
“we met the secondary endpoint which was distant metastasis-free survival which is of course takes more time to mature”
Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:05:01
2027
Bancel said Moderna and Merck hope to have the melanoma treatment available to patients in 2027 and that the factory in Massachusetts is ready.
“we hope in 2027 and then we're going to try to make it as fast as we can The factory is ready in Massachusetts”
Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:06:24
Undated
Luke Timmerman notes that Merck launched Gardasil and Pfizer-Wyeth launched Prevnar, two commercially successful vaccines, before Clark joined Genocea.
“Merck had come out with Gardasil and Pfizer-Wyeth had come out with Prevnar.”
Luke Timmerman · Ep19: Chip Clark, 0:25:07
Undated
Dean Lee, a Recursion co-founder, is president of Merck Research Labs and remains on Recursion's board.
“Dean is now the president of Merck Research Labs. He's one of my co-founders. He's on the board of Recursion still today”
Chris Gibson · AI & Computational Biology With Recursion's Chris Gibson, Ph.D., 0:03:46
Undated
Moderna develops its cancer treatments in partnership with Merck.
“Our oncology practice, our cancer treatments is done in partnership with Merck.”
Brice Challamel · #249 Brice Challamel: How Moderna is Using AI to Disrupt Modern Healthcare, 0:18:50
Undated
Sheller spent about 13 years at Sanofi, then moved to the biotech Kyowa Kirin, and has now been at Merck for over eight years.
“I spent about 13 years at large pharma at Sanofi and went to a small biotech, Keowakirin, shortly thereafter, before coming back into large pharma here at Merck for over eight years.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:08:58
Undated
Andy Lee, a former Sanofi colleague of Sheller, moved Merck from a fully outsourced clinical operations model to an in-house one.
“So he came into Merck and really shifted the paradigm from outsourced, fully outsourced model to bringing everything in-house.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:10:06
Undated
Merck's clinical operations model uses about 60% of its own headcount and about 40% functional service provider staff.
“So he brought everything in-house and built an operating model where we have, you know, 60% headcount through our company and then 40% or so through functional service provider.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:10:35
Undated
Sheller says unit-priced outsourcing contracts fit poorly because a safety signal can require extra monitoring, forcing change orders.
“if you have unitized pricing for a given study, X number of monitoring visits, X number of phone calls to a site, that's not the real world because you might have a safety signal where you need extra monitoring.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:15:14
Undated
Merck received its first approval for a product from Peloton Therapeutics within two years of acquiring the company.
“I'll share the Peloton example that came forward with a product that we got our first approval within two years of acquiring Peloton.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:17:36
Undated
Merck acquired a HIF2-alpha inhibitor from Peloton Therapeutics, with VHL-associated renal cell carcinoma as its first indication.
“we brought in the HIF2-alpha inhibitor from Peloton and renal cell carcinoma and VHL was our first indication.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:25:06
Undated
Sheller says the Acceleron acquisition, with a large phase three program, was probably Merck's most challenging integration.
“Accelerant had a large phase three program that was probably the most challenging integration.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:20:41
Undated
During the Peloton integration, Sheller hired a summer intern to shadow the team and write the integration playbook that became Merck's operations standard.
“I actually hired one of my summer interns to extend her stay for a project to shadow us and build the playbook out.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:21:37
Undated
Sheller cites Merck's Prometheus acquisition as a return to immunology, an area Merck had not been in for a while.
“That was an area we haven't been in in a while with the Prometheus acquisition, for example.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:26:12
Undated
Sheller says Merck wants to use AI and natural language processing to trend non-important protocol deviations so teams can focus on serious ones.
“that's where AI can help me trend the non-important deviations for the oversight.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:38:30
Undated
Some research sites told Merck they would not run a trial unless non-physician sub-investigators, such as nurse practitioners, were allowed under the R3 changes, and Merck changed its process.
“hey, look, we're not going to do this trial unless you do apply the R3 changes and having non-physician investigators or sub-investigators in the trial.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:44:11
Undated
Merck created the Let's Talk Trials education campaign for the whole clinical research industry rather than for Merck alone.
“Let's Talk Trials is something that we created for the industry, for clinical research as a whole. It's not specific to Merck.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:49:38
Undated
Sheller says she has built an automation hub at Merck, linked to the organization's functions through matrix leads.
“So I build an automation hub and I'm pairing it up through the functions in our organization.”
Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:53:28
Undated
Ghodsi said Databricks customer Merck created a model called Teddy, which stands for transformer enabled drug discovery.
“customer Merck, uh, that in the life science space created a model called Teddy. Teddy stands for transformer enabled drug discovery.”
Ali Ghodsi · AI Enterprise - Databricks & Glean | BG2 Guest Interview, 0:04:47
Undated
Ghodsi described the Teddy model as a transformer that predicts what is missing from a genome and learns the gene regulatory network, which he said helps with drug discovery.
“it instead can figure out which genome is missing if you remove a genome. So it really understands the gene regulatory network”
Ali Ghodsi · AI Enterprise - Databricks & Glean | BG2 Guest Interview, 0:05:17
Undated
Ben Comer says Merck has a small-molecule product targeting PCSK9.
“Merck's got a small molecule product now targeting PCSK9.”
Ben Comer · Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D., 0:09:14
Undated
Aris Baras says Merck donated over $2 billion over many years to its ivermectin program against river blindness.
“Merck donated something like over $2 billion over many, many years to continue donating and supporting that program.”
Aris Baras · Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D., 0:50:25